Atlas FDA

QIAGEN therascreen® FGFR RGQ RT-PCR Kit

FDA premarket approval P180043/S007 · decided 2025-10-03

Approval details

PMA number
P180043
Supplement
S007
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
QIAGEN therascreen® FGFR RGQ RT-PCR Kit
Generic name
Somatic gene mutation detection system
Applicant
QIAGEN GmbH
Date received
2024-03-22
Decision date
2025-10-03
Days to decision
560 days
Decision code
APPR
Product code
OWD
Advisory committee
Medical Genetics
Expedited review
No
Location
Hilden
Statement
Approval for an update to the software used to interpret the amplification curve for a positive sample or positive control during the PCR reaction.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
QIAstat-Dx BCID GPF Plus AMR Panel (K254194)QIAGEN GmbH2026-08-06
QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini B (K254032)QIAGEN GmbH2026-03-09
QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini B (K252329)QIAGEN GmbH2025-10-22
QIAstat-Dx Respiratory Panel Plus; QIAstat-Dx Respiratory Panel Mini (K250080)QIAGEN GmbH2025-08-27
QIAstat-Dx GI Panel 2 Mini B (K250324)QIAGEN GmbH2025-02-28
QIAstat-Dx GI Panel 2 Mini B&V (K243813)QIAGEN GmbH2025-01-08
QIAstat-Dx Meningitis/Encephalitis (ME) Panel (K242256)QIAGEN GmbH2024-10-29
QIAstat-Dx Respiratory Panel Mini (K242353)QIAGEN GmbH2024-10-25